C4 Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
C4 Therapeutics, Inc. (CCCC) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $11.14 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11.14M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14.46M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $18.07M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21.95M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $11.14M 10-K · filed 2026-02-26 |
| 2024-12-31 | $14.46M 10-K · filed 2025-02-27 |
| 2023-12-31 | $18.07M 10-K · filed 2024-02-22 |
| 2022-12-31 | $21.95M 10-K · filed 2023-02-23 |
| 2022-09-30 | $22.95M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $23.95M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $24.76M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $10.57M 10-K · filed 2022-02-24 |
| 2021-09-30 | $4.54M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $4.84M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $5.15M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $5.47M 10-K · filed 2021-03-11 |
| 2020-09-30 | $5.79M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |